Xenotransplantation - The current status and prospects

D. K.C. Cooper, R. Gaston, D. Eckhoff, J. Ladowski, T. Yamamoto, L. Wang, H. Iwase, H. Hara, M. Tector, A. J. Tector

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


Introduction There is a continuing worldwide shortage of organs from deceased human donors for transplantation into patients with end-stage organ failure. Genetically engineered pigs could resolve this problem, and could also provide tissues and cells for the treatment of conditions such as diabetes, Parkinson's disease and corneal blindness. Sources of data The current literature has been reviewed. Areas of agreement The pathobiologic barriers are now largely defined. Research progress has advanced through the increasing availability of genetically engineered pigs and novel immunosuppressive agents. Life-supporting pig kidneys and islets have functioned for months or years in nonhuman primates. Areas of controversy The potential risk of transfer of a pig infectious microorganism to the recipient continues to be debated. Growing points Increased attention is being paid to selection of patients for initial clinical trials. Areas timely for developing research Most of the advances required to justify a clinical trial have now been met.

Original languageEnglish (US)
Pages (from-to)5-14
Number of pages10
JournalBritish Medical Bulletin
Issue number1
StatePublished - Mar 1 2018
Externally publishedYes


  • cells
  • genetic-engineering
  • organs
  • pig
  • xenotransplantation

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Xenotransplantation - The current status and prospects'. Together they form a unique fingerprint.

Cite this